Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 453,735,920 | 511,844,582 | 561,378,936 | 604,363,420 | 629,412,126 | 2,760,734,984 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 453,735,920 | 511,844,582 | 561,378,936 | 604,363,420 | 629,412,126 | 2,760,734,984 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 2,760,734,984 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 453,735,920 | 511,844,582 | 561,378,936 | 604,363,420 | 629,412,126 | 2,760,734,984 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 13,734,456 | 9,251,603 | 9,629,978 | 101,304,972 | 52,614,894 | 186,535,903 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 15,146,613 | 17,212,855 | 23,432,437 | 14,052,058 | 14,919,939 | 84,763,902 |
| 11 | Total support. Add lines 7 through 10 | 3,032,249,527 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2019 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2019 |
(iii) Distributable Amount for 2019 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2019 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2019: | ||||
| a From 2014....... | ||||
| b From 2015....... | ||||
| c From 2016....... | ||||
| d From 2017....... | ||||
| e From 2018....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2019 distributable amount | ||||
|
i
Carryover from 2014 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2019 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2019 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2019, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2019. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2020. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2015..... | ||||
| b Excess from 2016..... | ||||
| c Excess from 2017..... | ||||
| d Excess from 2018..... | ||||
| e Excess from 2019..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A | CLINICAL CARE AS ONE OF THE LEADING CANCER CENTERS IN THE WORLD, DANA-FARBER CANCER INSTITUTE (DFCI) PROVIDES COMPASSIONATE, COMPREHENSIVE, AND PERSONALIZED CARE TO ADULTS AND CHILDREN WITH CANCER, BLOOD DISORDERS, AND RELATED DISEASES. IN FISCAL YEAR 2020, OUR EXPERT CLINICIANS AND CAREGIVERS AT OUR SPECIALIZED TREATMENT CENTERS WORKED TOGETHER TO DELIVER THE LATEST THERAPIES TO OUR PATIENTS THROUGH 1,421 INPATIENT ADMISSIONS, 313,358 OUTPATIENT MD VISITS, AND 174,239 INFUSION TREATMENTS. SINCE ITS FOUNDING IN 1947 BY SIDNEY FARBER, MD, DANA-FARBER HAS FOLLOWED HIS VISION FOR A CANCER CENTER THAT IS JUST AS DEDICATED TO DISCOVERIES IN CANCER RESEARCH AS IT IS TO DELIVERING EXPERT, COMPASSIONATE CARE. DANA-FARBER IS A FOUNDING MEMBER OF DANA-FARBER/HARVARD CANCER CENTER AND ONE OF 51 NCI-DESIGNATED COMPREHENSIVE CANCER CENTERS IN THE U.S. DANA-FARBER IS THE ONLY HOSPITAL RANKED IN THE TOP FOUR NATIONALLY BY U.S. NEWS AND WORLD REPORT IN BOTH ADULT AND PEDIATRIC CANCER CARE. IN 2020, WE OFFERED MORE THAN 1,100 CLINICAL TRIALS. FORM 990, PART III, LINE 4B RESEARCH SCIENTIFIC WORK AT DANA-FARBER IS BASED ON THE PREMISE THAT BASIC AND CLINICAL INVESTIGATION ARE COMPLEMENTARY AND REINFORCING ACTIVITIES. TO ENCOURAGE THIS CROSS-POLLINATION OF IDEAS, THE INSTITUTE HAS DEVELOPED AN ORGANIZATIONAL FRAMEWORK THAT FOSTERS COLLABORATIONS AMONG INVESTIGATORS FROM DIFFERENT DISCIPLINES. THE RESULT IS AN INTENSE SCIENTIFIC IMPACT ON A GROUP OF DISEASES THAT CONTINUE TO REPRESENT ONE OF HUMANITYS GREATEST HEALTH CHALLENGES. SOME RECENT ADVANCES INCLUDE: IDENTIFYING POTENTIAL ANTICANCER DRUGS: USING A MASSIVE SEARCH STRATEGY, RESEARCHERS AT DANA-FARBER AND THE BROAD INSTITUTE OF MIT AND HARVARD IDENTIFIED DOZENS OF DRUGS FOR CONDITIONS RANGING FROM DIABETES TO INFLAMMATION THAT HAVE POTENTIAL FOR TREATING CANCER. IMMUNOTHERAPY FOR ORAL CANCER: A CLINICAL TRIAL LED BY DANA-FARBER INVESTIGATORS INDICATED THAT IMMUNOTHERAPY GIVEN BEFORE OTHER TREATMENTS FOR ORAL CANCER CAN TRIGGER AN IMMUNE RESPONSE THAT SHRINKS TUMORS, POTENTIALLY PROVIDING LONG-TERM BENEFIT FOR PATIENTS. EARLY WARNING OF BREAST CANCER RECURRENCE: SCIENTISTS AT DANA-FARBER AND THE BROAD INSTITUTE DEVELOPED A HIGHLY SENSITIVE TYPE OF BLOOD BIOPSY THAT CAN POTENTIALLY DETECT THE RECURRENCE OF BREAST CANCER YEARS BEFORE TRADITIONAL APPROACHES CAN. IDENTIFYING PATIENTS AT HIGH RISK OF MYELOMA: FOR PEOPLE WITH A COMMON PRECURSOR OF MULTIPLE MYELOMA, A GENOMIC TEST OF BONE MARROW TISSUE CAN INDICATE WHETHER THEY HAVE A HIGH RISK OF DEVELOPING THE FULL-BLOWN FORM OF THE DISEASE, DANA-FARBER SCIENTISTS REPORTED. THOSE FOUND TO BE AT INCREASED RISK COULD BENEFIT FROM CLOSE MONITORING OF THEIR HEALTH OR FROM CLINICAL TRIALS OF THERAPIES INTENDED TO HALT THE PROGRESSION OF THE DISEASE. TARGETED AGENT SHOWS PROMISE IN UTERINE CANCER: IN ITS FIRST CLINICAL TRIAL IN PATIENTS WITH A HARD-TO-TREAT FORM OF UTERINE CANCER, A TARGETED DRUG THAT SUBJECTS TUMOR CELLS TO MASSIVE AMOUNTS OF DNA DAMAGE CAUSED TUMORS TO SHRINK IN NEARLY ONE-THIRD OF PATIENTS, DANA-FARBER LEADERS OF THE TRIAL REPORTED. THE DRUG, ADAVOSERTIB, TARGETS A PROTEIN CALLED WEE1 THAT PLAYS A KEY ROLE IN THE CELL CYCLE. PREDICTING EFFECTIVE THERAPIES FOR SOLID TUMORS: DANA-FARBER RESEARCHERS DEVELOPED A NEW METHOD OF SCREENING THOUSANDS OF DRUGS IN FRESHLY COLLECTED HUMAN TUMOR CELLS. BY USING FRESH TUMOR CELLS, THE TECHNIQUE MAY PROVE MORE ACCURATE THAN TRADITIONAL DRUG-SCREENING APPROACHES THAT EMPLOY LABORATORY CELLS THAT MAY HAVE BEEN COLLECTED WEEKS OR EVEN YEARS EARLIER. NEW DRUG COMBINATION FOR OVARIAN CANCER PRODUCED ENCOURAGING RESULTS: IN ITS FIRST CLINICAL TRIAL, A DRUG THAT TARGETS A PROTEIN CRITICAL FOR CANCER CELL GROWTH SHOWED CONSIDERABLE PROMISE IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH A COMMON FORM OF OVARIAN CANCER, DANA-FARBER INVESTIGATORS REPORTED. PATIENTS WHO RECEIVED THE DRUG, BERZOSERTIB, PLUS CHEMOTHERAPY LIVED SUBSTANTIALLY LONGER BEFORE THEIR DISEASE BEGAN TO WORSEN THAN DID THOSE TREATED WITH CHEMOTHERAPY ALONE. EARLY KIDNEY CANCER DETECTION: A NEW LIQUID BIOPSY, WHICH DETECTS DNA FROM TUMOR CELLS IN A BLOOD SAMPLE, CAN DETECT KIDNEY CANCERS AT AN EARLY STAGE WITH HIGH ACCURACY, DANA-FARBER RESEARCHERS FOUND. IF THE TEST PROVES EFFECTIVE IN LARGER STUDIES, IT COULD HELP DOCTORS FIND MORE KIDNEY CANCERS BEFORE THEYVE SPREAD, REDUCING MORTALITY FROM THE DISEASE. COFFEE AND COLON CANCER SURVIVAL: IN A STUDY INVOLVING MORE THAN 1,000 PATIENTS WITH METASTATIC COLORECTAL CANCER, CONSUMPTION OF A FEW CUPS OF COFFEE A DAY WAS ASSOCIATED WITH LONGER SURVIVAL AND A LOWER RISK OF THE CANCER WORSENING, DANA-FARBER RESEARCHERS FOUND. CLINICAL RESEARCH DURING A PANDEMIC: BY ADOPTING ALTERNATIVES TO IN-PERSON VISITS DURING THE COVID-19 PANDEMIC, DANA-FARBER WAS ABLE TO KEEP CLINICAL TRIALS LARGELY ON COURSE, A STUDY FOUND. NOT ONLY DID ALMOST ALL PATIENTS REMAIN ON TRIALS AT THE INSTITUTE DURING THE FIRST SURGE OF THE PANDEMIC, BUT NEW ENROLLMENTS CONTINUED AS WELL. DRUG COMBINATION FOUND BENEFICIAL FOR EARLY-STAGE BREAST CANCER: ADDING THE IMMUNOTHERAPY AGENT ATEZOLIZUMAB TO A THREE-DRUG CHEMOTHERAPY REGIMEN CAN IMPROVE THE LIKELIHOOD THAT EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER WILL RECEDE TO UNDETECTABLE LEVELS, DATA FROM A CLINICAL TRIAL LED BY DANA-FARBER/BRIGHAM AND WOMENS CANCER CENTER INVESTIGATORS INDICATED. IMMUNOTHERAPY COMBINATION FOR ADVANCED KIDNEY CANCER: AN IMMUNOTHERAPY AGENT PLUS A TARGETED DRUG SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL THE LENGTH OF TIME BEFORE CANCER WORSENS AND REDUCED THE RISK OF DEATH COMPARED TO A SINGLE-AGENT TREATMENT IN PATIENTS WITH ADVANCED KIDNEY CANCER, A CLINICAL TRIAL LED BY DANA-FARBER INVESTIGATORS FOUND. DRUG TARGETING HARD-TO-BLOCK GENE SHOWS PROMISE IN LUNG AND BOWEL TUMORS: A NOVEL DRUG THAT TARGETS A MUTATED FORM OF THE KRAS GENE THE MOST COMMONLY ALTERED ONCOGENE IN HUMAN CANCERS AND ONE LONG CONSIDERED "UNDRUGGABLE" SHRANK TUMOR IN MOST PATIENTS WITH NON-SMALL CELL LUNG CANCER, COLORECTAL CANCER, AND OTHER SOLID TUMOR, DANA-FARBER SCIENTISTS REPORTED. CANCER TREATMENT AND RESEARCH DURING COVID-19 OUTBREAK: THE COVID-19 PANDEMIC IMPACTED VIRTUALLY EVERY ASPECT OF CANCER CARE AND RESEARCH FROM INTRODUCING NEW RISKS FOR CANCER PATIENTS TO DISRUPTING THE DELIVERY OF CANCER TREATMENT AND THE CONTINUITY OF CANCER RESEARCH, A REVIEW OF SCIENTIFIC LITERATURE BY DANA-FARBER RESEARCHERS FOUND. THE FINDINGS SUGGEST THAT WHILE COVID-19 HAS COMPLICATED CANCER TREATMENT, IT HAS ALSO SPURRED CREATIVE SOLUTIONS TO CHALLENGES IN CLINICAL CARE. IDENTIFYING PATIENTS WITH LOBULAR BREAST CANCER AT HIGHEST RISK OF RECURRENCE: A TEST THAT SCANS THE ACTIVITY OF 70 GENES IN BREAST CANCER TISSUE CAN HELP IDENTIFY PATIENTS WITH INVASIVE LOBULAR CARCINOMA WHO HAVE A HIGH RISK OF THE CANCER RECURRING OR PROGRESSING AFTER SURGERY, A DANA-FARBER STUDY FOUND. MEDICAID EXPANSION AND LOWER CANCER MORTALITY: IN STATES THAT HAVE EXPANDED MEDICAID AVAILABILITY AS PART OF THE AFFORDABLE CARE ACT, MORTALITY RATES FOR THREE MAJOR FORMS OF CANCER WERE SIGNIFICANTLY LOWER THAN IN STATES THAT HAD NOT EXPANDED THEIR MEDICAID, A STUDY BY RESEARCHERS AT DANA-FARBER AND BRIGHAM AND WOMENS HOSPITAL FOUND. DATA FROM THE STUDY SUGGEST THAT THE IMPROVEMENT RESULTS FROM CANCERS BEING DIAGNOSED AT AN EARLIER STAGE IN STATES WITH MEDICAID EXPANSION. CAR T-CELL THERAPY EFFECTIVE IN HIGH-RISK NON-HODGKIN LYMPHOMA: A CAR T-CELL THERAPY KNOWN AS AXI-CEL DROVE CANCER CELLS TO UNDETECTABLE LEVELS IN NEARLY 80% OF PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA IN A PHASE 2 CLINICAL TRIAL, DANA-FARBER CANCER INVESTIGATORS REPORTED. MORTALITY RATES FOR CANCER SURGERY DECLINE FOR BLACK AND WHITE PATIENTS: MORTALITY RATES AFTER CANCER SURGERY DECLINED FOR BLACK AS WELL AS WHITE PATIENTS DURING A RECENT TEN-YEAR PERIOD, ALTHOUGH THE MORTALITY GAP BETWEEN THE TWO GROUPS DID NOT NARROW, A STUDY BY DANA-FARBER RESEARCHERS FOUND. THE FINDINGS SUGGEST THAT MORE TARGETED EFFORTS ARE NEEDED TO REDUCE THIS DISPARITY. |
| FORM 990, PART III, LINE 4C | COMMUNITY BENEFITS THE ROLE OF DANA-FARBER'S COMMUNITY BENEFITS OFFICE IS TO SUPPORT THE INSTITUTE'S GOAL TO REDUCE CANCER RISK AMONG MEDICALLY UNDERSERVED POPULATIONS. TO THAT END, WE WORK WITH CITY AND STATE HEALTH DEPARTMENTS, COMMUNITY PARTNERS, AND BOSTON-BASED COALITIONS TO ASSESS AND MONITOR THE NEEDS OF LOCAL RESIDENTS WITH RESPECT TO CANCER CONTROL. WE ARE ON THE FRONT LINES OF SUPPORTING AND COLLABORATING ON PROGRAMS DESIGNED TO ELIMINATE DISPARITIES IN BREAST, COLON, SKIN, AND PROSTATE CANCER; EDUCATE DIVERSE POPULATIONS ABOUT TOBACCO CESSATION, HUMAN PAPILLOMAVIRUS (HPV) PREVENTION AND SCREENING, AND CLINICAL TRIALS; AND STRENGTHEN THE SUPPORT SYSTEM FOR MEDICALLY UNDERSERVED POPULATIONS. IN SHORT, WE ARE COMMITTED TO MAKING DANA-FARBER'S CARE AND RESEARCH FINDINGS MORE ACCESSIBLE TO EVERYONE WITHIN AND OUTSIDE ITS WALLS. IN FY 2020: PROGRAM VOLUMES WERE IMPACTED SIGNIFICANTLY BY THE COVID-19 PANDEMIC AND CITY AND STATE RESTRICTIONS ON IN-PERSON PROGRAMMING. COMMUNITY BENEFITS OFFICE WAS ABLE TO ADAPT PROGRAMMING FOR A VIRTUAL FORMAT AND PROVIDED EDUCATION VIRTUALLY BY LEVERAGING THE ONLINE PLATFORMS OF COMMUNITY PARTNERS SUCH AS UNION CAPITAL BOSTON (UCB). IN ADDITION, THE COMMUNITY BENEFITS OFFICE PIVOTED BY PROVIDING MASK DONATIONS AND EMERGENCY GRANT FUNDING TO COMMUNITY PARTNERS TO ADDRESS FOOD ACCESS AND OTHER CRITICAL COMMUNITY NEEDS DURING THE PANDEMIC. DANA-FARBERS MAMMOGRAPHY SERVICES PROVIDED 1,620 MAMMOGRAMS IN THE VAN AND AT THE MAMMOGRAPHY SUITE IN ROXBURY. THE SUN SAFETY PROGRAM WAS ABLE TO PIVOT BY ADAPTING ITS CURRICULUM AND PROVIDING A VIRTUAL SUN SAFETY EDUCATION SESSION TAILORED TO COMMUNITIES OF COLOR IN PARTNERSHIP WITH UCB, WHICH ENGAGED APPROXIMATELY 90 COMMUNITY RESIDENTS. IN PREPARATION FOR THE POSSIBILITY THAT THE STATE OF MASSACHUSETTS AND THE CITY OF BOSTON WOULD ALLOW IN-PERSON SCREENINGS AND EDUCATION, SUN SAFETY STAFF ALSO PROVIDED VIRTUAL TRAINING TO A TEAM OF STUDENT HEALTH EDUCATORS. THE TOBACCO TREATMENT PROGRAM RECEIVED 126 REFERRALS AND PROVIDED 95 INDIVIDUAL TOBACCO CESSATION COUNSELING SESSIONS TO 40 PATIENTS. 29 PARTICIPANTS WERE ABLE TO REDUCE THEIR TOTAL NUMBER OF CIGARETTES SMOKED PER DAY, AND 15 OF THESE REPORTED BEING ABLE TO QUIT COMPLETELY. A TOTAL OF 519 INDIVIDUALS WERE REACHED THROUGH 27 COMMUNITY EDUCATION, OUTREACH, AND SCREENING EVENTS. DFCI AWARDED $200K IN EMERGENCY GRANT FUNDING TO TWELVE COMMUNITY-BASED PARTNER ORGANIZATIONS IN THE BOSTON AREA THAT ARE ON THE FRONT LINES IN ADDRESSING FOOD ACCESS, HOUSING SECURITY, AND OTHER CRITICAL COMMUNITY NEEDS. DFCI ALSO DISTRIBUTED OVER 50,000 MASKS TO 31 ORGANIZATIONS IN GREATER BOSTON. DFCI LAUNCHED A NEW PUBLIC SERVICE ANNOUNCEMENT ENCOURAGING INDIVIDUALS TO GET SCREENED FOR CANCER, WHICH AIRED ON MULTIPLE CABLE NETWORKS IN QUINCY AND SELECT BOSTON NEIGHBORHOODS, FOLLOWING THE STATES PAUSE ON PREVENTIVE CARE. DUE TO CITY AND STATE RESTRICTIONS DANA-FARBER HAD TO TEMPORARILY SUSPEND SUN SAFETY VAN OPERATIONS, BUT COMMUNITY BENEFITS STAFF WERE ABLE TO PROVIDE TWO VIRTUAL TABLE TALK SESSIONS ON SUN SAFETY AND HPV-RELATED CANCER PREVENTION, REACHING APPROXIMATELY 120 RESIDENTS. FORM 990, PART VI, LINE 2 FAMILY OR BUSINESS RELATIONSHIP FAMILY RELATIONSHIP: JOHN O'CONNOR AND LAURA SEN BUSINESS RELATIONSHIP: RICHARD LUBIN, CHRISTOPHER HADLEY AND JANE BROCK-WILSON Business Relationship: Josh Bekenstein, Andrew Kaplan, Nancy Lotane Form 990, Part VI, Line 11B PROCESS USED TO REVIEW THE FORM 990 THE DANA-FARBER CANCER INSTITUTE TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST & YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED BY THE DFCI TAX MANAGER, AS WELL AS THE DFCI OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS SUBMITTED FOR DFCI AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE REVIEWS THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST & YOUNG LLP WITH THE IRS. |
| FORM 990, PART VI, LINE 12C | MONITORING & ENFORCEMENT OF CONFLICT OF INTEREST POLICY THE OFFICE OF GENERAL COUNSEL AND THE TAX DEPARTMENT DRAFT A CONFLICT OF INTEREST DISCLOSURE QUESTIONNAIRE EACH YEAR AND REQUIRES THAT ALL TRUSTEES, OFFICERS, AND KEY EMPLOYEES FILL OUT A QUESTIONNAIRE IN ORDER TO IDENTIFY POTENTIAL DISCLOSURES FOR DFCI'S RETURNS. THE OFFICE OF GENERAL COUNSEL COMPILES THE LIST OF DISCLOSURES AND GATHERS FINANCIAL DATA FROM THE ACCOUNTS PAYABLE AND PAYROLL DEPARTMENT FOR ALL ORGANIZATIONS, EMPLOYEES, INDEPENDENT CONTRACTORS, AND OTHER MISCELLANEOUS TRANSACTIONS WHICH WERE DISCLOSED BY ALL INDIVIDUALS. ONCE ALL OF THIS INFORMATION IS COMPILED, THE OFFICE OF GENERAL COUNSEL AND THE TAX DEPARTMENT GO THROUGH EACH TRANSACTION AND DISCLOSURE TO DETERMINE WHAT NEEDS TO BE DISCLOSED ON THE TAX RETURN. THE TAX DEPARTMENT AND THE OFFICE OF GENERAL COUNSEL ALSO DISCUSS IF THERE ARE ANY OTHER KNOWN TRANSACTIONS THAT HAVE NOT BEEN DISCLOSED. IF THERE ARE ANY QUESTIONS REGARDING SUCH SITUATION, THE OFFICE OF GENERAL COUNSEL WILL DISCUSS THE QUESTIONS WITH THE INDIVIDUAL TRUSTEES, OFFICERS AND KEY EMPLOYEES INVOLVED. IN ADDITION TO THE PROCESS DESCRIBED ABOVE, THE GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS ANNUALLY REVIEWS ANY NEW CONFLICT OF INTEREST DISCLOSURES AND THEY ADDRESS ANY ISSUES THAT MAY ARISE. The Governance Committee is also responsible to bring any major issues related to the conflict of interest policy to the Conflict of Interest Oversight Committee if deemed necessary. PER DFCI'S CONFLICT OF INTEREST POLICY, IN ORDER TO AVOID A CONFLICT OF INTEREST OR AN APPEARANCE OF A CONFLICT OF INTEREST: 1. A TRUSTEE SHOULD NOT PARTICIPATE IN A VOTE ON A TRANSACTION IN WHICH THE TRUSTEE OR FAMILY MEMBER HAS A FINANCIAL INTEREST AND SHOULD DISCLOSE ANY POTENTIAL CONFLICT BEFORE DFCI ACTS ON THE TRANSACTION. 2. A TRUSTEE, A MEMBER OF HIS OR HER FAMILY, OR AN ENTITY WITH WHICH ONE OR MORE OF THEM HAS A MATERIAL INTEREST, MAY NOT DO BUSINESS WITH DFCI UNLESS EXPRESSLY AUTHORIZED BY DFCI AFTER FULL DISCLOSURE. 3. A TRUSTEE SHOULD FULLY DISCLOSE HIS OR HER ASSOCIATION (INCLUDING EMPLOYMENT, CONSULTING, OR MEMBERSHIP ON A GOVERNING BOARD BY THE TRUSTEE OR A FAMILY MEMBER) WITH AN ENTITY THAT COMPETES WITH OR HAS INTERESTS CONFLICTING WITH THOSE OF DFCI AND SHOULD REFRAIN FROM PARTICIPATING IN ANY VOTE IF THE VOTE AFFECTS DFCI. ONCE A DISCLOSURE HAS BEEN MADE, DFCI'S OFFICE OF GENERAL COUNSEL REVIEWS SUCH CONFLICT WITH THE CHAIR OF THE BOARD WHO DETERMINES IF A CONFLICT EXISTS. WHEN A CONFLICT EXISTS, THE APPROPRIATE COMMITTEE OF THE BOARD OF TRUSTEES DETERMINES IF A MORE ADVANTAGEOUS ALTERNATIVE WITHOUT A CONFLICT OF INTEREST EXISTS AND WHETHER ENTERING INTO THE ARRANGEMENT IS IN THE BEST INTEREST OF DANA-FARBER. |
| FORM 990, PART VI, LINE 15A | PROCESS FOR DETERMINING COMPENSATION OF PRESIDENT PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF SEPTEMBER 2020. |
| FORM 990, PART VI, LINE 15B | PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES. THE PRESIDENT MAKES A RECOMMENDATION AS TO THE COMPENSATION OF THOSE INDIVIDUALS WHO ARE DISQUALFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. FOR KEY EMPLOYEES WHO ARE NOT DISQIALFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF COMPENSATION FOR THOSE INDIVIDUALS. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE PRESIDENT AND COMPENSATION COMMITTEE BI-ANNUALLY RECEIVES THE REPORT OF AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE APPROVAL OF THE COMPENSATION COMMITTEE IS REPORTED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES AND TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF SEPTEMBER 2020. |
| FORM 990, PART VI, LINE 19 | AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS TO THE PUBLIC GOVERNING DOCUMENTS THE GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. THE GOVERNING DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY DANA-FARBER CANCER INSTITUTE'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2001 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. |
| FORM 990, PART VII, SECTION B | THE AMOUNT PAID TO BOND BROTHERS AND WALSH BROTHERS, INC. INCLUDED COSTS FOR BUILDING SERVICES AND MATERIALS. HOWEVER, THE ORGANIZATION WAS UNABLE TO OBTAIN INFORMATION TO BREAKOUT THE EXACT AMOUNT FOR MATERIAL COSTS. |
| FORM 990, PART XI, LINE 9 | OTHER CHANGES IN NET ASSETS CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATES $ 192,657,436 CHANGE IN VALUE OF SWAP AGREEMENT $ (11,700,882) PENSION ADJUSTMENT $ (6,006,605) ---------------------- TOTAL OTHER CHANGES IN NET ASSETS $ 174,949,949 |
| Software ID: | |
| Software Version: |